BioRx added to Zemaira distribution network

Published on October 30, 2012 at 12:20 AM · No Comments

BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Zemaira® [alpha-1 proteinase inhibitor (human)]. Zemaira is indicated for chronic augmentation and maintenance therapy in individuals with alpha1-antitrypsin (AAT) deficiency and clinical evidence of emphysema. It was originally approved by the Food and Drug Administration (FDA) in 2003 and is one of only four FDA-approved treatments available today.

"We are very excited to be added to the Zemaira distribution network," said Eric Hill, co-founder of BioRx. "The addition of Zemaira enables us to extend our reach to more patients within the alpha-1 community. We are also excited to expand our partnership with CSL Behring into the alpha-1 marketplace." 

AAT deficiency is an inherited condition that raises the risk of developing certain types of lung disease, such as emphysema, especially in smokers. People with AAT deficiency do not have enough of a protein called "alpha-1 antitrypsin" (also called "alpha-1 proteinase inhibitor") in their blood. AAT protein is produced by the liver and helps to protect the lungs from everyday irritants such as smoke, fumes, dust and pollen. Zemaira, a human-derived alpha-1 proteinase inhibitor, acts to inhibit the activity of another protein, neutrophil elastase, which, left unchecked, can degrade the lining of the lungs and lead to pulmonary disease.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post